Literature DB >> 17258073

High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes.

Christine L O'Keefe1, Ramon Tiu, Lukasz P Gondek, Jennifer Powers, Karl S Theil, Matt Kalaycio, Alan Lichtin, Mikkael A Sekeres, Jaroslaw P Maciejewski.   

Abstract

OBJECTIVE: Unbalanced chromosomal aberrations are common in myelodysplastic syndromes and have prognostic implications. An increased frequency of cytogenetic changes may reflect an inherent chromosomal instability due to failure of DNA repair. Therefore, it is likely that chromosomal defects in myelodysplastic syndromes may be more frequent than predicted by metaphase cytogenetics and new cryptic lesions may be revealed by precise analysis methods.
METHODS: We used a novel high-resolution karyotyping technique, array-based comparative genomic hybridization, to investigate the frequency of cryptic chromosomal lesions in a cohort of 38 well-characterized myelodysplastic syndromes patients; results were confirmed by microsatellite quantitative PCR or single nucleotide polymorphism analysis.
RESULTS: As compared to metaphase karyotyping, chromosomal abnormalities detected by array-based analysis were encountered more frequently and in a higher proportion of patients. For example, chromosomal defects were found in patients with a normal karyotype by traditional cytogenetics. In addition to verifying common abnormalities, previously cryptic defects were found in new regions of the genome. Cryptic changes often overlapped chromosomes and regions frequently identified as abnormal by metaphase cytogenetics.
CONCLUSION: The results underscore the instability of the myelodysplastic syndromes genome and highlight the utility of array-based karyotyping to study cryptic chromosomal changes which may provide new diagnostic information.

Entities:  

Mesh:

Year:  2007        PMID: 17258073      PMCID: PMC2613764          DOI: 10.1016/j.exphem.2006.09.016

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  46 in total

1.  Progressive preleukemia with a chromosomally abnormal clone in a kindred with the Estren-Dameshek variant of Fanconi's anemia.

Authors:  P Nowell; G Bergman; E Besa; D Wilmoth; B Emanuel
Journal:  Blood       Date:  1984-11       Impact factor: 22.113

2.  Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer.

Authors:  G Kristiansen; Y Yu; S Petersen; O Kaufmann; K Schlüns; M Dietel; I Petersen
Journal:  Eur J Cancer       Date:  2001-06       Impact factor: 9.162

3.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

4.  A longitudinal study of human age-related chromosomal analysis in skin fibroblasts.

Authors:  A B Mukherjee; S Thomas
Journal:  Exp Cell Res       Date:  1997-08-25       Impact factor: 3.905

5.  Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan.

Authors:  H F Tien; C H Wang; S M Chuang; J M Chow; F Y Lee; M C Liu; Y C Chen; M C Shen; D T Lin; K H Lin
Journal:  Cancer Genet Cytogenet       Date:  1994-05

6.  Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors.

Authors:  A Kallioniemi; O P Kallioniemi; D Sudar; D Rutovitz; J W Gray; F Waldman; D Pinkel
Journal:  Science       Date:  1992-10-30       Impact factor: 47.728

7.  Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.

Authors:  H Caron; P van Sluis; J de Kraker; J Bökkerink; M Egeler; G Laureys; R Slater; A Westerveld; P A Voûte; R Versteeg
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

8.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

Authors:  P Morel; M Hebbar; J L Lai; A Duhamel; C Preudhomme; E Wattel; F Bauters; P Fenaux
Journal:  Leukemia       Date:  1993-09       Impact factor: 11.528

9.  Sex chromosome loss and aging: in situ hybridization studies on human interphase nuclei.

Authors:  M Guttenbach; B Koschorz; U Bernthaler; T Grimm; M Schmid
Journal:  Am J Hum Genet       Date:  1995-11       Impact factor: 11.025

10.  The mammalian gamma-tubulin complex contains homologues of the yeast spindle pole body components spc97p and spc98p.

Authors:  S M Murphy; L Urbani; T Stearns
Journal:  J Cell Biol       Date:  1998-05-04       Impact factor: 10.539

View more
  9 in total

Review 1.  Whole genome scanning as a cytogenetic tool in hematologic malignancies.

Authors:  Jaroslaw P Maciejewski; Ghulam J Mufti
Journal:  Blood       Date:  2008-05-27       Impact factor: 22.113

Review 2.  Updates in cytogenetics and molecular markers in MDS.

Authors:  Ramon V Tiu; Valeria Visconte; Fabiola Traina; Anita Schwandt; Jaroslaw P Maciejewski
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

Review 3.  Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Authors:  Aziz Nazha; Mikkael A Sekeres; Steven D Gore; Amer M Zeidan
Journal:  Oncologist       Date:  2015-07-20

Review 4.  The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?

Authors:  Zaher K Otrock; Ramon V Tiu; Jaroslaw P Maciejewski; Mikkael A Sekeres
Journal:  Expert Rev Hematol       Date:  2013-02       Impact factor: 2.929

5.  Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Jaroslaw P Maciejewski; Aristotle A N Giagounidis; Kenton Wride; Robert Knight; Azra Raza; Alan F List
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

6.  Combined comparative genomic hybridization and single-nucleotide polymorphism array detects cryptic chromosomal lesions in both myelodysplastic syndromes and cytopenias of undetermined significance.

Authors:  Andrew G Evans; Ausaf Ahmad; W Richard Burack; M Anwar Iqbal
Journal:  Mod Pathol       Date:  2016-07-08       Impact factor: 7.842

Review 7.  Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?

Authors:  Sebastian Stintzing; Ralf Kemmerling; Tobias Kiesslich; Beate Alinger; Matthias Ocker; Daniel Neureiter
Journal:  J Biomed Biotechnol       Date:  2011-05-15

8.  Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.

Authors:  Johann-Christoph Jann; Daniel Nowak; Florian Nolte; Stephanie Fey; Verena Nowak; Julia Obländer; Jovita Pressler; Iris Palme; Christina Xanthopoulos; Alice Fabarius; Uwe Platzbecker; Aristoteles Giagounidis; Katharina Götze; Anne Letsch; Detlef Haase; Richard Schlenk; Gesine Bug; Michael Lübbert; Arnold Ganser; Ulrich Germing; Claudia Haferlach; Wolf-Karsten Hofmann; Maximilian Mossner
Journal:  J Med Genet       Date:  2017-06-09       Impact factor: 6.318

9.  Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.

Authors:  María Abáigar; Cristina Robledo; Rocío Benito; Fernando Ramos; María Díez-Campelo; Lourdes Hermosín; Javier Sánchez-Del-Real; Jose M Alonso; Rebeca Cuello; Marta Megido; Juan N Rodríguez; Guillermo Martín-Núñez; Carlos Aguilar; Manuel Vargas; Ana A Martín; Juan L García; Alexander Kohlmann; M Consuelo Del Cañizo; Jesús M Hernández-Rivas
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.